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SUMMARY 20 
Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a disabling and life-threatening 21 
disease for which plasma-derived C1 inhibitor (pdC1-INH) is an effective treatment. Poor responses to 22 
pdC1-INH are rare. The aim of this prospective study was to evaluate the pharmacokinetics and 23 
pharmacodynamics of C1 inhibitor (C1-INH) in a C1-INH-HAE patient with poor response to treatment 24 
to investigate the mechanism underlying poor response to pdC1-INH. Seventeen C1-INH-HAE patients 25 
with normal responses to treatment served as retrospective controls. In the poor response patient, 26 
higher than standard doses of pdC1-INH did not change the PK but led to normalization of PD 27 
parameters and symptoms disappeared, recurring upon dose reduction. Therefore, we conclude that 28 
hyperactivation of the complement and contact systems in highly symptomatic C1-INH-HAE patients 29 
does not account for interpatient variability in response to pdC1-INH, which may be connected to 30 
differences in hepatic clearance of infused pdC1-INH. 31 
 32 
CAPSULE SUMMARY 33 
Pharmacokinetic data in a patient with poor treatment response to plasma-derived C1 inhibitor 34 
compared with 17 control patients suggest that poor treatment response likely depends on increased 35 
catabolism, but not through interaction with target proteases. 36 
 37 
KEY WORDS 38 
hereditary angioedema, C1 inhibitor, complement, contact system, pharmacokinetic, protein 39 
catabolism 40 
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ABBREVIATIONS 41 
AUCτ area under the concentration-time curve at dosing interval τ 42 
C1-INH C1 inhibitor 43 
C1-INH-HAE Hereditary angioedema due to C1 inhibitor deficiency 44 
CL apparent total plasma clearance  45 
Css concentration at steady-state 46 
HK high-molecular-weight kininogen 47 
PD pharmacodynamics(s) 48 
pdC1-INH plasma-derived C1 inhibitor 49 
PK pharmacokinetic(s) 50 
r Pearson correlation coefficient 51 
T1/2 elimination half-life 52 
τ dosing interval 53 
Vd apparent volume of distribution 54 
 55 
 56 
To the Editor, 57 
Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent 58 
swelling attacks, mediated by bradykinin which is released upon activation of the contact system in 59 
patients lacking C1 inhibitor (C1-INH) (1). Replacement therapy with intravenous plasma-derived C1-60 
INH (pdC1-INH) aims at restoring control of bradykinin release by maintaining protective C1-INH 61 
activity trough levels (2). Approved doses of pdC1-INH, 1000 IU twice weekly for prophylaxis (3), are 62 
generally effective but can fail in some patients with severe C1-INH-HAE (4). 63 
 64 
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This prospective, single-center, open-label study was designed to assess whether catabolism of C1-65 
INH influences the response to pdC1-INH therapy in poor-response patients with severe C1-INH-HAE. 66 
Pharmacokinetic (PK) and pharmacodynamic (PD) parameters were evaluated before and after 67 
repetitive administration of high pdC1-INH doses (Berinert, CSL Behring). During the loading period, 68 
daily 3000 IU pdC1-INH infusions were repeated until 24-h post-infusion functional C1-INH levels 69 
exceeded 70% of normal. In the maintainance period, 3000 IU were administered 3-times weekly for 5 70 
weeks, followed by 2000 IU twice weekly for 3 weeks. Adverse events, vital signs, and concomitant 71 
medications were monitored, revealing no safety findings of note. 72 
One poor-response patient was enrolled; a 75-year-old woman with C1-INH-HAE due to a c.1475T>A 73 
(p.Met492Lys) mutation. She experienced up to 100 attacks annually. On-demand pdC1-INH and 74 
icatibant provided only limited benefit, prophylaxis with pdC1-INH, tranexamic acid, and danazol 75 
remained ineffective. At the time of the study, she received on-demand pdC1-INH or icatibant up to 76 
twice weekly. 77 
Seventeen C1-INH-HAE patients with normal responses to pdC1-INH served as retrospective controls, 78 
providing blood samples obtained before and after 20 attacks that were treated with pdC1-INH 79 
(Berinert, CSL Behring). 80 
Laboratory measurements were performed as previously described (5, 6). Functional and antigenic 81 
C1-INH concentrations were best fitted by 1-compartment models. P-Pharm population PK modeling 82 
software was used (version 3, Simed). For the poor-response patient, the elimination half-life was 83 
derived from estimated PK parameters (T1/2=0.693*apparent volume of distribution[VD]/total plasma 84 
clearance[CL]). The area under the concentration-time curve during a dosing interval τ (AUCτ) was 85 
estimated by the trapezoidal rule. The average plasma concentration at steady-state (Css) during τ was 86 
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calculated as AUCτ/τ. Statistical analyses were performed using STATA software (version 13, Stata 87 
Corporation). Quantitative data were summarized as mean, standard deviation, and coefficient of 88 
variation. Relationships between quantitative variables were analyzed with the Pearson correlation 89 
coefficient (r). Comparisons between patients were made using a 1-sample t-test. 90 
The study was conducted in accordance with the Helsinki Declarations and approved by the local 91 
Independent Ethics Committee (Ospedale Luigi Sacco, Milan). Written informed consent was obtained 92 
from the poor-response patient. The control patients had given written consent for their samples to 93 
be used for research purposes.  94 
 95 
The poor-response patient had pre-infusion levels of functional C1-INH, C4, and C1q below detection 96 
limits, 25% of normal for antigenic C1-INH, and 60% for cleaved high-molecular-weight kininogen 97 
(HK). After 3 days with 3000 IU pdC1-INH, the maintenance period could start. 98 
During 5 weeks with 3000 IU 3-times weekly, mean pre-infusion functional and antigenic C1-INH 99 
levels were 46% and 57% of normal, respectively, increasing to 86% and 53% post-infusion (Table I). 100 
C4 and C1q and cleaved HK reached the normal ranges on Days 4 and 2 and remained there (Figure 1). 101 
The patient took additional on-demand icatibant once. 102 
During 3 weeks with 2000 IU twice weekly, mean pre-infusion functional and antigenic C1-INH levels 103 
were 18% and 30% of normal, increased to 53% and 71% post-infusion (Table I), but decreased rapidly 104 
thereafter (Online Repository, Figure 1). C1q remained within the normal range, C4 decreased to 105 
below 60% of normal, and HK remained above 40% (Figure 1). The patient experienced 5 attacks 106 
treated with icatibant and 1 without additional treatment. 107 
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Functional and antigenic C1-INH levels estimated for the poor-response patient from population PK 108 
models correlated well with the observed levels (r=0.85; p<0.001 and r=0.87; p<0.001, respectively). 109 
At steady-state, 9000 IU pdC1-INH weekly were estimated to result in average weekly systemic 110 
exposures (AUC) of functional and antigenic C1-INH of 11487 h.% (dose/CL) and 12941 h.%, 111 
respectively, and average Css of 68.4% (AUC/168 h) and 77.1% (Online Repository, Figure 1). 4000 IU 112 
weekly were estimated to result in average AUC of 5833 h.% and 7329 h.% and average Css of 34.6% 113 
and 43.1%. Apparent total plasma clearance (CL) of antigenic C1-INH was estimated at 0.51 IU/(h.%), 114 
Vd at 25.4 IU/%, and T1/2 at 34.3 h. Estimated CL of functional C1-INH was significantly lower for the 115 
control patients than for the poor-response patient (0.37 vs. 0.56 IU/[h.%], p=0.002); Vd showed no 116 
significant difference (35.0 vs. 27.3 IU/%, p=0.19). 117 
Plasma recovery of C1-INH after infusion of pdC1-INH was lower and clearance faster in our poor-118 
response patient than in normal responders. She had no evidence of autoimmune or other disease 119 
and normal transaminase plasma levels. Concurrently with the worsening of symptoms, she had 120 
depletion of C4 and C1q and massive HK cleavage, indicating a profound degree of instability in the 121 
complement and contact systems. With high doses of pdC1-INH, PD parameters normalized and 122 
symptoms disappeared, recurring upon dose reduction. At either dose, PK parameters were 123 
consistent, with similar percentages of protein cleared from plasma. 124 
In some patients with acquired C1-INH deficiency, symptoms are induced by autoantibodies that 125 
consume C1-INH (7). In our poor-response patient, however, no C1-INH antibodies were detected. 126 
Other physiologic pathways of C1-INH catabolism include interaction with target proteases or binding 127 
to hepatic asialoglycoprotein receptors (8). 128 
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In our poor-response patient, high doses of pdC1-INH apparently normalized PD parameters and 129 
controlled clinical symptoms without changing the PK, suggesting that clearance of C1-INH was not 130 
dependent on the catabolic pathways provided by protease-inhibitor interaction.  131 
Therefore, changes in the expression of hepatic asialoglycoprotein receptors, related to still 132 
undefined circumstances, could explain increased C1-INH clearance in our poor-response patient. 133 
Cirrhosis, often accompanied by increased expression of asialoglycoprotein receptors (9), was 134 
excluded. 135 
 136 
We conclude that differences in treatment response to pdC1-INH replacement therapy may be 137 
connected to differences in hepatic clearance of the infused C1-INH protein rather than 138 
hyperactivation of the complement and contact systems in highly symptomatic C1-INH-HAE patients. 139 
Sincerely,  140 
Marco Cicardi M.D., Andrea Zanichelli M.D., Chiara Suffritti Ph.D., and Maddalena A. Wu M.D., 141 
Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan and ASST 142 
Fatebenefratelli Sacco, Milan, Italy; Thomas Machnig M.D., CSL Behring, Marburg, Germany; Annalisa 143 
De Silvestri M.D., Clinical Epidemiology and Biometric Unit - Foundation IRCCS Policlinico San Matteo, 144 
Pavia, Italy; Mario Regazzi Pharm.D., Clinical and Experimental Pharmacokinetics Unit - Foundation 145 
IRCCS Policlinico San Matteo, Pavia, Italy; Carmine Tinelli M.D., Clinical Epidemiology and Biometric 146 
Unit - Foundation IRCCS Policlinico San Matteo, Pavia, Italy 147 
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FIGURE LEGENDS 153 
 154 
Figure 1: C1q, C4, and cleaved HK levels during the study in the poor-response patient with C1-INH-155 
HAE.  156 
Normal levels (expressed as % of normal plasma levels in healthy subjects, mean values and 95% 157 
confidence intervals) are 98.6% (97.6% to 99.6%) for C1q, 96.7% (91.7% to 101.6%) for C4, and ≤ 30% 158 
for HK. 159 
Abbreviations: C1-INH-HAE = hereditary angioedema due to C1 inhibitor deficiency; HK = high-160 
molecular-weight kininogen. 161 
 162 
 163 
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Table I: Functional and antigenic C1-INH concentrations in the poor-response patient during the 
maintenance period 
 Mean concentration in % (SD; CV) 
Pre-infusion 
 
Post-infusion,  
10 min after end of 
infusion 
Functional C1-INH 
9000 IU/week (3000 IU, 3 times 
weekly) 
46 
(30; 66) 
86 
(27; 31) 
4000 IU/week (2000 IU, twice weekly) 18 
(10; 59) 
53 
(10; 20) 
Antigenic C1-INH 
9000 IU/week (3000 IU, 3 times 
weekly) 
57 
(23; 40) 
112 
(23; 21) 
4000 IU/week (2000 IU, twice weekly) 30 
(12; 42) 
71 
(15; 22) 
C1-INH = C1 inhibitor; CV = coefficient of variation; SD = standard deviation. 
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ONLINE REPOSITORY 
Figure 1:  Observed and predicted concentrations of functional and antigenic C1-INH 
activities in the poor-response patient with C1-INH-HAE. 
Observed (○) and predicted (solid lines) concentra*ons of func*onal (panel A) and 
antigenic (panel B) C1-INH activities (expressed as % of normal activity in healthy 
subjects). Normal functional and antigenic C1-INH levels ranged from 65% to 146% and 
68% to 115%, respectively. 
Abbreviations: τ = dosing interval; AUC = area under the concentration-time curve; C1-
INH = C1 inhibitor; CL = apparent total plasma clearance; Css = concentration at steady-
state; CV% = coefficient of variation; T1/2 = elimination half-life; Vd = apparent volume 
of distribution. 
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B. Antigenic C1-INH
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0
Dose: 9000 IU 
(3000 IU, 3 times/week)
Dose: 4000 IU 
(2000 IU, 2 times/week)
t = 3 
days
t = 4 
days
t = 2 
days
during 
7 days
AUCt (h x %) 3821 6328 3791 12941
Css (%) 79.6 74.0 79.0 77.1
t = 3 
days
t = 4 
days
during 
7 days
AUCt (h x %) 2391 4848 7329
Css (%) 33.2 50.5 43.1
Number of administrations: 26
Dose administered: 2000 or 3000 IU
Total number of observations: 64
CL = 0.51 IU/(h x %) CV% = 7.02
Vd = 25.4 IU/% CV% = 1.06
T1/2 = 34.3 hours
Time (Hours)
A. Functional C1-INH
C
on
ce
nt
ra
tio
n 
(%
)
200 400 600 800 1000 1200 1400 1600 18000
120
80
180
20
100
200
40
140
60
160
0
Dose: 9000 IU 
(3000 IU, 3 times/week)
Dose: 4000 IU 
(2000 IU, 2 times/week)
t = 3 
days
t = 4 
days
t = 2 
days
during 
7 days
AUCt (h x %) 3096 4976 3420 11487
Css (%) 64.5 69.3 71.1 68.4
t = 3 
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t = 4 
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during 
7 days
AUCt (h x %) 1192 4641 5833
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Number of administrations: 26
Dose administered: 2000 or 3000 IU
Total number of observations: 63
CL = 0.56 IU/(h x %) CV% = 7.72
Vd = 27.3 IU/% CV% = 12.1
T1/2 = 33.8 hours
